$TCRX News

HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow

Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target

Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Says Cancer Therapy Data Support Move to Phase 3 Trial

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate